SCHEMBL4964696

SCHEMBL4964696

CC(=O)c1cccc(NC(=O)OC(C)C)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.68
ALOX15 P16050 1/20 0.68
CYP1A2 P05177 1/20 0.61
RAB9A P51151 4/20 0.60
SMN1; SMN2 Q16637 4/20 0.60
NPC1 O15118 3/20 0.60
MAPT P10636 1/20 0.60
HTT P42858 1/20 0.60
LMNA P02545 1/20 0.57
KMT2A Q03164 6/20 0.57
MEN1 O00255 4/20 0.57
KDM4E B2RXH2 1/20 0.56
ALDH1A1 P00352 4/20 0.56
MAPK1 P28482 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
TP53 P04637 1/20 0.56
GAA P10253 1/20 0.56
TDP1 Q9NUW8 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
POLB P06746 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2096845 0.83 CYP1A2 (0.69) HPGDCYP1A2RAB9ASMN1; SMN2NPC1
SCHEMBL10749929 0.82 HPGD (0.69) HPGDALOX15CYP1A2RAB9ASMN1; SMN2
SCHEMBL31331879 0.82 HPGD (0.69) HPGDALOX15CYP1A2RAB9ASMN1; SMN2
SCHEMBL10192111 0.82 ALOX15 (0.69) HPGDALOX15CYP1A2RAB9ASMN1; SMN2
Chlorpropham SCHEMBL54464 0.81 HPGD (1.00) HPGDALOX15CYP1A2RAB9ASMN1; SMN2
SCHEMBL31287149 0.81 HPGD (0.68) HPGDALOX15CYP1A2RAB9ASMN1; SMN2
Chlorpropham SCHEMBL22437601 0.81 HPGD (1.00) HPGDALOX15CYP1A2RAB9ASMN1; SMN2
SCHEMBL18804823 0.81 HPGD (0.68) HPGDALOX15CYP1A2RAB9ASMN1; SMN2
Chlorpropham SCHEMBL8538082 0.81 HPGD (1.00) HPGDALOX15CYP1A2RAB9ASMN1; SMN2
SCHEMBL27256414 0.81 HPGD (0.68) HPGDALOX15CYP1A2RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101351495-A fatty acid amide hydrolase inhibitors ORGANON NV (NL) 2009-01-21 CN disclosed
EP-1969051-A2 INHIBITORS OF FATTY ACID AMIDE HYDROLASE N.V. Organon (NL) 2008-09-17 EP disclosed
WO-2008024139-A2 INHIBITORS OF FATTY ACID AMIDE HYDROLASE N.V. ORGANON (NL) 2008-02-28 WO disclosed
WO-2007079180-A2 INHIBITORS OF FATTY ACID AMIDE HYDROLASE N.V. ORGANON (NL) 2007-07-12 WO disclosed
US-20070155747-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE KADMUS PHARMACEUTICALS, INC. (US) 2007-07-05 US disclosed
US-3938986-A ISOPROPYL N-PHENYLCARBAMATE OR ISOPROPYL N-(3-CHLOROPHENYL)CARBAMATE AND 4-CHLOROPHENYL N-METHYLCARBAMATE PPG INDUSTRIES, INC. (US) 1976-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155747-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ABHD6 HPGD 437/4885ALOX15 67/4885CYP1A2 507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.